



August 29,2022

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting held on August 29,2022**

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 12.45 pm and ended at 2:55 pm), the Audited Financial Results for Financial Year ended June 30, 2022 were approved.

We are enclosing herewith the following:

- a. Audited Financial Results for the Financial Year ended June 30, 2022, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015;
- b. Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company;
- c. Press Release; and
- d. A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results

We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, *inter alia*, have recommended a final dividend of Rs.11.50 per equity share, for the financial year ended June 30, 2022. The dividend shall be paid between November 28, 2022 to December 18, 2022, on approval of the Members at the 55<sup>th</sup> Annual General Meeting.

Kindly take the same on record.

Thanking you.

Yours faithfully,  
**For Procter & Gamble Health Limited**

**Zeal Shah**  
**Company Secretary**

**Procter & Gamble Health Limited**

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8<sup>th</sup> Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

[www.pghealthindia.com](http://www.pghealthindia.com)

**PROCTER & GAMBLE HEALTH LIMITED**

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.  
CIN No. L99999MH1967PLC013726, e-mail: investorgrievance.im@pg.com

Highly Restricted

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE YEAR AND QUARTER ENDED 30 JUNE 2022**

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)
		Three months ended 30th June 2022	Preceding Three months ended 31st March 2022	Corresponding Three months ended 30th June 2021	Year ended 30th June 2022	Year ended 30th June 2021
		Audited	Unaudited	Audited	Audited	Audited
1.	Revenue from Operations	29,589.0	26,782.0	28,540.0	111,441.0	100,873.0
2.	Other income	310.0	235.0	242.0	1,319.0	1,810.0
3.	<b>Total income (1+2)</b>	<b>29,899.0</b>	<b>27,017.0</b>	<b>28,782.0</b>	<b>112,760.0</b>	<b>102,683.0</b>
4.	Expenses					
	a) Cost of materials consumed	7,247.0	7,426.0	7,340.0	32,372.0	28,923.0
	b) Purchases of stock-in-trade	499.0	409.0	814.0	2,083.0	2,116.0
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	1,114.0	191.0	437.0	(475.0)	173.0
	d) Employee benefits expense	4,213.0	4,500.0	4,659.0	16,756.0	15,366.0
	e) Depreciation and amortisation expense	747.0	612.0	716.0	2,708.0	3,004.0
	f) Impairment	73.0	-	-	73.0	-
	g) Finance Costs	2.0	14.0	18.0	42.0	80.0
	h) Other expenses	10,539.0	7,379.0	10,445.0	33,864.0	29,693.0
	<b>Total expenses (4)</b>	<b>24,434.0</b>	<b>20,531.0</b>	<b>24,429.0</b>	<b>87,423.0</b>	<b>79,355.0</b>
5.	Profit before exceptional items and tax (3-4)	5,465.0	6,486.0	4,353.0	25,337.0	23,328.0
6.	Less: Exceptional items	-	-	-	-	-
7.	Profit before tax (5-6)	5,465.0	6,486.0	4,353.0	25,337.0	23,328.0
8.	Tax expenses					
	Current Tax	1,233.0	1,722.0	1,322.0	6,502.0	6,360.0
	Deferred Tax	113.0	(59.0)	(377.0)	4.0	(490.0)
	Tax for earlier years	-	(293.0)	19.0	(421.0)	(222.0)
9.	Net Profit for the period/ year (7-8)	4,119.0	5,116.0	3,389.0	19,252.0	17,680.0
10.	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	i. Re-measurement gains/(losses) on defined benefit plans	324.0	128.0	551.0	94.0	56.0
	ii. Income tax effect	(82.0)	(32.0)	(139.0)	(24.0)	(14.0)
	Total Other Comprehensive Income, net of tax	242.0	96.0	412.0	70.0	42.0
11.	Total Comprehensive Income for the period/year (9+10)	4,361.0	5,212.0	3,801.0	19,322.0	17,722.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	59,989.0	68,711.0
14.	Earnings per equity share (of Rs 10/- each) *(not annualised)					
	(a) Basic and Diluted (in Rs.)	* 24.8	* 30.8	* 20.4	* 116	* 106.5

**Notes:**

- The above audited financial results for the quarter and year ended June 30, 2022 have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their Meeting held on August 29, 2022.
- Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
- The figures of last quarter are the balancing figures between audited figures in respect of full year and published year to date figures upto the third quarter of financial year.
- The Board of Directors at its meeting held on August 29, 2022 has recommended for the current year final dividend of Rs. 11.5 per equity share (nominal value of 10 per equity share) aggregating to Rs. 19,089 lakhs subject to approval of members at the ensuing Annual General Meeting of the Company.
- The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
- Previous period figures have been regrouped/ reclassified wherever necessary.

For and on behalf of the Board of Directors of  
Procter & Gamble Health Limited.

  
Milind Thatte  
Managing Director

Place : Mumbai  
Date : 29 August 2022  
Please visit us at our website [www.pghealthindia.com](http://www.pghealthindia.com)



**PROCTER & GAMBLE HEALTH LIMITED**

Notes:

**1. Statement of Assets and Liabilities**

(₹ in lakhs)

			As at June 30, 2022 [Audited]	As at June 30, 2021 [Audited]
<b>Non-current assets</b>				
(a)	Property, plant and equipment		10,635	9,337
(b)	Capital work-in-progress		4,060	3,915
(c)	Investment property		260	295
(d)	Right-of-use assets		267	747
(e)	Intangible assets		4	12
(f)	Financial assets			
	(i) Loans		599	541
	(ii) Other financial assets		876	818
(g)	Deferred tax assets (net)		1,965	1,991
(h)	Other non-current assets		1,632	609
(i)	Non-current tax assets (Net)		8,386	7,637
	<b>Total non-current assets</b>		<b>28,684</b>	<b>25,902</b>
<b>Current assets</b>				
(a)	Inventories		11,521	11,837
(b)	Financial assets			
	(i) Trade receivables		8,344	5,981
	(ii) Cash and cash equivalents		31,940	46,405
	(iii) Bank balances other than (ii) above		513	486
	(iv) Loans		157	145
	(v) Other financial assets		746	560
(c)	Other current assets		7,467	7,300
	<b>Total current assets</b>		<b>60,688</b>	<b>72,714</b>
	<b>TOTAL ASSETS</b>		<b>89,372</b>	<b>98,616</b>
<b><u>EQUITY AND LIABILITIES</u></b>				
<b>Equity</b>				
(a)	Equity share capital		1,660	1,660
(b)	Other equity		59,989	68,711
	<b>Total Equity</b>		<b>61,649</b>	<b>70,371</b>
<b>Non-Current Liabilities</b>				
(a)	Financial liabilities			
	(i) Lease liabilities		-	286
(c)	Provisions		4,080	4,005
(b)	Other non-current liabilities		60	57
	<b>Total non-current liabilities</b>		<b>4,140</b>	<b>4,348</b>
<b>Current liabilities</b>				
<b>Financial liabilities</b>				
(a)	Trade payables			
	(i) total outstanding dues of micro enterprises and small enterprises		1,533	600
	(ii) total outstanding dues of creditors other than micro enterprises and small enterprises		16,068	17,291
(b)	Lease Liabilities		283	475
(c)	Other financial liabilities		3,025	2,367
(d)	Other current liabilities		924	822
(e)	Provisions		1,026	1,917
(f)	Current tax liabilities (net)		724	425
	<b>Total current liabilities</b>		<b>23,583</b>	<b>23,897</b>
	<b>TOTAL EQUITY &amp; LIABILITIES</b>		<b>89,372</b>	<b>98,616</b>



*Mohan*

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Procter & Gamble Health Limited

Report on the Audit of the Financial Results

### Opinion

We have audited the accompanying annual financial results of **Procter & Gamble Health Limited** ("the Company") for the year ended June 30, 2022 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended June 30, 2022.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Board of Directors' Responsibility for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the



accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



# HARIBHAKTI & CO. LLP

Chartered Accountants

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## Other Matter

The Statement includes the results for the quarter ended June 30, 2022, being the balancing figure between audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Haribhakti & Co. LLP  
Chartered Accountants  
ICAI Firm Registration No.103523W / W100048

Hemant J. Bhatt  
Partner

Membership No. 036834  
UDIN: 22036834AQDUKV2699  
Place: Mumbai  
Date: August 29, 2022





## Procter & Gamble Health Announces Fourth Quarter and Fiscal Year Results

Sales for the fiscal up by 10%

Sales for the quarter up by 3%

**Mumbai, August 29, 2022:** Procter & Gamble Health Limited announced today its financial results for the quarter and fiscal year ended 30th June, 2022. In a year impacted by macroeconomic challenges the company recorded sales of ₹ 1,092 crore for the fiscal year ending 30th June 2022, up by 10% Vs year ago supported by strong established brands in healthcare space trusted by healthcare professionals. Profit After Tax (PAT) for the year ended 30th June 2022 is ₹ 193 crores, up by 9%, despite unprecedented commodity inflations during this fiscal.

The company has recorded a strong performance with sales of ₹289 Crores in the Quarter ending June 30th, up by 3% Vs year ago. Domestic sales were up by 8% however quarter performance was impacted by economic and financial challenges in Sri Lanka.

**Mr. Milind Thatte, Managing Director, P&G Health India,** said, *“We have registered consistent growth in revenue in recent quarters in a challenging environment which saw the industry facing headwinds across many categories. This has been a result of extensive efforts across all fronts to improve awareness and accessibility of our superior, quality products, and better serve our customers, consumers, partners and communities. We continued our efforts to create awareness through integrated campaigns encouraging consumers to identify symptoms and seek timely treatment. Our team stepped up on scientific education efforts for healthcare practitioners through accredited symposiums, roundtables and congresses with leading medical and pharmacy associations. This year, we also launched the ‘P&G Health Academy’, a virtual platform that brings together health experts from across the globe to converge, share and learn. We strengthened our go-to-market strategy through new initiatives that aim to increase reach and distribution. We continued to invest in strengthening public health through our flagship CSR program ‘SEHAT’ (meaning health) with 9 bespoke initiatives, while making strong progress on gender diversity, equality and inclusion through our i-RISE program.”*

The Board of Directors have recommended a final dividend of ₹ 11.50 per Equity Share, for the Financial Year ending June 30, 2022. Considering interim dividend of ₹ 41 per share, total dividend payout for the fiscal will be ₹ 52.50 per share, subject to the approval of final dividend by shareholders of the company at the ensuing 55th Annual General Meeting.

### About Procter & Gamble Health Limited:

Procter & Gamble Health Limited is one of India's largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

### About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. The P&G operates in approximately 70 countries worldwide.

### CONTACTS

#### Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | [mehra.r@pg.com](mailto:mehra.r@pg.com)
- Paromita Kundu | [kundu.p.1@pg.com](mailto:kundu.p.1@pg.com)

#### Investor Relations Contact:

- Flavia Machado | [machado.f.1@pg.com](mailto:machado.f.1@pg.com)

### Registered Office :

**Procter & Gamble Health Limited**  
 CIN: L99999MH1967PLC013726  
 Godrej One, 8<sup>th</sup> Floor, Pirojshanagar,  
 Eastern Express Highway, Vikhroli East,  
 Mumbai 400 079 | Tel: (91-22) 6866 9000

### Site Address:

**Procter & Gamble Health Limited**  
 CIN: L99999MH1967PLC013726  
 Usgaon, Ponda Taluka,  
 Goa 403 407 | Tel: (91-832) 2347105  
[www.pghealthindia.com](http://www.pghealthindia.com)



August 29,2022

To,  
The Corporate Relations Department  
The BSE Limited  
of Corporate Services  
Towers,  
Dalal Street, Mumbai 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block, Phiroze Jeejeebhoy  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub: Declaration with respect to Audit Report with unmodified opinion to the Audited Financial Results for the Financial Year ended June 30, 2022**

We hereby declare that Audited Financial Results for the Financial Year ended June 30, 2022 which have been approved by the Board of Directors of the Company at meeting held today, i.e., August 29,2022, the Statutory Auditors, Haribhakti & Co. LLP have not expressed any modified opinion(s) in their Audit Report.

The above declaration is made pursuant to Regulation 33 (3) (d) of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Kindly take the same on record.

Thanking you.

Yours faithfully,  
***For Procter & Gamble Health Limited***

*Zeal Shah*  
*Company Secretary*

**Procter & Gamble Health Limited**

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8<sup>th</sup> Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

[www.pghealthindia.com](http://www.pghealthindia.com)